Document is current
Any future updates will be listed below
-
Authors
Dauphinot, Virginie
Laurent, Marie
Prodel, Martin
Civet, Alexandre
Vainchtock, Alexandre
Moutet, Claire
Krolak-Salmon, Pierre
Garnier-Crussard, Antoine
-
Funding
Funding for this research was provided by:
Roche France, France
- License Information
-
More Information
Article History
Received: 4 August 2023
Accepted: 16 July 2024
First Online: 26 July 2024
Declarations
:
: Information regarding the collection of individual data, with the aim of performing research on routine care, was provided to the patients. No signed consent to participate was then required, but patients may refuse the use of their data for research purpose. The present study is a secondary analysis of the MEMORA cohort and received an ethical approval by the local Institutional Review Board of the University Hospital of Lyon (Hospices Civils de Lyon, Lyon, France). It was conducted following the MR-004 reference methodology edited by the French data protection supervisory authority (CNIL: Commission Nationale de l’Informatique et Libertés) allowing to ensure data protection in research contexts and which follows the EU General Data Protection Regulation. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
: Not applicable.
: The authors declare no competing interests.Virginie Dauphinot, Claire Moutet, and Antoine Garnier-Crussard are working at the University Hospital of Lyon. Pierre Krolak-Salmon was working at University Hospital of Lyon at the time of the study. Marie Laurent, Martin Prodel and Alexandre Vainchtock are working for the HEVA company. Alexandre Civet is working for Roche.Independent of this work, AGC is an unpaid sub-investigator or principal investigator in NCT04867616 (UCB Pharma), NCT04241068 (Biogen), NCT03446001 (TauRx Therapeutics), NCT03444870 (Roche), NCT04374253 (Roche), NCT04777396 (Novo Nordisk), NCT04777409 (Novo Nordisk), NCT04770220 (Alzheon), NCT05423522 (Medesis Pharma).Independent of this work, PKS is an unpaid sub-investigator or principal investigator in NCT04867616 (UCB Pharma), NCT04241068 (Biogen), NCT03446001 (TauRx Therapeutics), NCT03444870 (Roche), NCT04374253 (Roche), NCT04777396 (Novo Nordisk), NCT04777409 (Novo Nordisk), NCT04770220 (Alzheon), NCT05423522 (Medesis Pharma), and provides consultancy for Biogen, Roche, Novartis, MSD, Lilly, Pfizer, Abbvie.
: .
